FDA-cleared profile

CARA System

Cara Medical, Ltd. · Fluoroscopy/Angiography · FDA-cleared (510(k))

Authorized purpose: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.

Clinical role
Preprocedural CT segmentation and cardiac-conduction roadmap overlay during fluoroscopy-guided procedures.
Images and patients
Fluoroscopy/Angiography · Heart/Cardiovascular
Key limitation
Keep in mind: The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.
  • Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Heart/Cardiovascular Input: Preprocedural cardiac CT in DICOM format and live fluoroscopy for overlay guidance.
  • Who uses it?Intended users: Qualified physicians and trained procedural staff performing adult cardiac procedure planning and guidance.
  • What does the software produce?Output: Reviewed three-dimensional cardiac anatomy and conduction-landmark roadmap with fluoroscopic overlay.
  • What is its most important limitation?Key limitation: The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.

Clinical takeaway. Clinical role: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical, AI/ML validation, and retrospective clinical testing: phantom CT-to-fluoroscopy registration (mean registration error of ≤ 2.0 mm); validation against annotations by trained technologists adjudicated by an interventional cardiologist (CT cardiac-chamber segmentation on 50 retrospective CT scans: all evaluated structures met criteria; fluoroscopic aortic segmentation on 480 images: Mean DSC = 0.962); and a retrospective clinical study on 403 patients evaluating the device's utility in visualizing the conduction system. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.
  • Exact FDA submission
  • Checked 2026-09-04

Added in P2 round17 from the exact FDA decision material; later product-family claims remain separate.

Workflow role
Preprocedural CT segmentation and cardiac-conduction roadmap overlay during fluoroscopy-guided procedures.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Preprocedural cardiac CT in DICOM format and live fluoroscopy for overlay guidance.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
Reviewed three-dimensional cardiac anatomy and conduction-landmark roadmap with fluoroscopic overlay.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Procedure-planning offices and operating or interventional rooms for adults older than 18 years.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified physicians and trained procedural staff performing adult cardiac procedure planning and guidance.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
The exact FDA document reports non-clinical, AI/ML validation, and retrospective clinical testing: phantom CT-to-fluoroscopy registration (mean registration error of ≤ 2.0 mm); validation against annotations by trained technologists adjudicated by an interventional cardiologist (CT cardiac-chamber segmentation on 50 retrospective CT scans: all evaluated structures met criteria; fluoroscopic aortic segmentation on 480 images: Mean DSC = 0.962); and a retrospective clinical study on 403 patients evaluating the device's utility in visualizing the conduction system. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Comprehensive non-clinical, AI/ML validation, and retrospective clinical performance testing were conducted to demonstrate substantial equivalence" … "CT-to-fluoroscopy registration testing validated geometric alignment between the CT-derived model and live fluoroscopy using landmark-based comparison against ground truth in phantom. The system achieved a mean registration error of ≤ 2.0 mm". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical, AI/ML validation, and retrospective clinical testing: phantom CT-to-fluoroscopy registration (mean registration error of ≤ 2.0 mm); validation against annotations by trained technologists adjudicated by an interventional cardiologist (CT cardiac-chamber segmentation on 50 retrospective CT scans: all evaluated structures met criteria; fluoroscopic aortic segmentation on 480 images: Mean DSC = 0.962); and a retrospective clinical study on 403 patients evaluating the device's utility in visualizing the conduction system. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Comprehensive non-clinical, AI/ML validation, and retrospective clinical performance testing were conducted to demonstrate substantial equivalence" … "CT-to-fluoroscopy registration testing validated geometric alignment between the CT-derived model and live fluoroscopy using landmark-based comparison against ground truth in phantom. The system achieved a mean registration error of ≤ 2.0 mm". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252500 FDA performance package for CARA System

  • DesignManufacturer nonclinical verification and validation of segmentation, anatomical landmark modeling, registration, and live fluoroscopy overlay
  • PopulationAdult preprocedural cardiac CT and representative fluoroscopy-guided workflow data described in K252500
  • Scopeexact submission
  • Tested versionCARA System cleared in K252500
  • IndependenceSponsor or vendor study

K252500

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252500 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Preprocedural cardiac CT in DICOM format and live fluoroscopy for overlay guidance.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · FDA 510(k) decision material K252500: CARA System

  2. Routing

    Source context, not route validation: DICOM CT ingestion with procedure-room fluoroscopy overlay; verify supported scanners, geometry, registration workflow, and failure handling locally.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA 510(k) decision material K252500: CARA System · CARA cardiac conduction visualization product-family overview

  3. AI processing

    Source context, not route validation: Planning workstation and procedure-room integration; current CARA Metis and Atlas materials describe the product family, not every K252500 configuration.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA 510(k) decision material K252500: CARA System · CARA cardiac conduction visualization product-family overview

  4. Returned objects

    Source context, not route validation: Reviewed three-dimensional cardiac anatomy and conduction-landmark roadmap with fluoroscopic overlay.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · FDA 510(k) decision material K252500: CARA System

  5. Viewer/worklist/report

    Unresolved route: Reviewed three-dimensional cardiac anatomy and conduction-landmark roadmap with fluoroscopic overlay.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · FDA 510(k) decision material K252500: CARA System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Planning workstation and procedure-room integration; current CARA Metis and Atlas materials describe the product family, not every K252500 configuration.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM CT ingestion with procedure-room fluoroscopy overlay; verify supported scanners, geometry, registration workflow, and failure handling locally.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only qualified physicians and trained procedural staff performing adult cardiac procedure planning and guidance. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K252500 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM CT ingestion with procedure-room fluoroscopy overlay; verify supported scanners, geometry, registration workflow, and failure handling locally.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The clinician must review the segmentation and landmarks. The software is an adjunct to, not a replacement for, procedural judgment, imaging review, or standard localization methods.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252500
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Fluoroscopy/Angiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-02-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

Twenty PubMed records and ten trial records were screened. Most are CARA acronym collisions; NCT05657912 and NCT05465655 concern CARA CDRS/CDRM rather than the K252500 CARA System. No evidence was promoted, and all 30 candidates remain quarantined. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision material, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K252500: CARA System

    U.S. Food and Drug Administration - Published 2026-02-20 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. CARA cardiac conduction visualization product-family overview

    Cara Medical - Accessed 2026-09-03

    Scope: productFamily, workflowRole, input, output, implementationCapabilities

Research history

  1. K252500 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243769

QFR (3.0)

QFR Solutions bv

Authorized purpose: QFR (3.0) uses paired coronary X-ray angiographic DICOM acquisitions to calculate three-dimensional vessel and lesion measurements and pressure-drop quantification for interventional cardiologist or researcher review in patients with coronary artery disease.

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2025-04-04
FDA-cleared K243884

TAVIPILOT

Caranx Medical

Authorized purpose: TAVIPILOT detects, tracks, and marks the non-coronary cusp and prosthetic valve on live fluoroscopy during specified adult femoral TAVR or TAVI procedures under physician control.

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2025-07-07
FDA-cleared K252099

Trinias

Shimadzu Corporation

Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.

Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Decision
2026-03-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history